At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XENE Xenon Pharmaceuticals
Post-Market Trading 05-10 16:41:43 EDT
40.54
-1.95
-4.59%
盘后40.54
+0.000.00%
16:01 EDT
High42.56
Low38.60
Vol527.88K
Open40.76
D1 Closing42.49
Amplitude9.32%
Mkt Cap3.06B
Tradable Cap2.82B
Total Shares75.46M
T/O21.47M
T/O Rate0.76%
Tradable Shares69.59M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Xenon Pharmaceuticals: A Strong Buy on Clinical Progress and Robust Financials
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.